The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...
In the past few weeks, some of the world’s biggest soda, snack and candy companies reported quarterly earnings, so this week ...
It’s hard to watch television without seeing advertisements for compounded GLP-1 weight-loss drugs cheaper than the authentic ...
Hims & Hers, which launched a Super Bowl ad touting its weight loss product offerings, markets a compounded version of semaglutide, the active ingredient in Ozempic and Wegovy. Shares of Hims ...
The Food and Drug Administration said Friday the shortage of Ozempic and Wegovy is over ... its weight-loss offerings in a Super Bowl ad as “affordable” and “doctor-trusted,” while ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Ozempic and Wegovy, the widely popular forms ... its sale of compounded GLP-1 drugs in a 60-second Super Bowl ad earlier this month, drawing some scrutiny and criticisms. The company bought ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results